SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
jgh12041-sup-0001-si.pdf1958K

Figures S1 Decision analytic model—non-injector.

jgh12041-sup-0002-si.pdf2751K

Figure S2 Decision analytic model—active PWID.

jgh12041-sup-0003-si.pdf5408K

Figure S3 Decision analytic model—former PWID.

jgh12041-sup-0004-si.jpeg386K

Figure S4 Cost-effectiveness acceptability curve—non-injector.

jgh12041-sup-0005-si.jpeg386K

Figure S5 Cost-effectiveness acceptability curve—active PWID.

jgh12041-sup-0006-si.jpeg385K

Figure S6 Cost-effectiveness acceptability curve—former PWID.

jgh12041-sup-0007-si.xlsx69K

Table S1 Disaggregated costs estimates for hepatitis C virus disease states.

jgh12041-sup-0008-si.xlsx47K

Table S2 Calculated lifetime costs and outcomes with 0%, 3%, and 5% discount rates.

jgh12041-sup-0009-si.xlsx45K

Table S3 Projected natural history of disease for hypothetical cohorts.

jgh12041-sup-0010-si.xlsx46K

Table S4 ICER one-way sensitivity analyses of selected model variables.

jgh12041-sup-0011-si.xlsx51K

Table S5 Projected costs and outcomes and incremental cost-effectiveness ratios for protease inhibitor treatment for chronic hepatitis C virus infection with genotype 1.

jgh12041-sup-0012-si.docx155K

Appendix S1 Additional explanations on model structure and assumptions.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.